Tenaya Therapeutics (TNYA) Equity Average (2020 - 2026)

Tenaya Therapeutics' Equity Average history runs 7 years deep, the most recent figure standing at $114.7 million for Q1 2026.

• In Q1 2026, Equity Average rose 8.11% year-over-year to $114.7 million; the TTM figure through Mar 2026 stood at $114.7 million (up 8.11% YoY), while the FY2025 annual figure was $108.1 million, down 6.96% from the prior year.
• Equity Average was $114.7 million for Q1 2026 at Tenaya Therapeutics, up from $103.1 million in the prior quarter.
• In the past five years, Equity Average ranged from a high of $263.8 million in Q1 2022 to a low of $91.3 million in Q3 2025.
• Historically, Equity Average has averaged $161.0 million across 5 years, with a median of $148.8 million in 2024.
• The sharpest annual moves came in 2022 and 2024: Equity Average jumped 401.06% in 2022, then plunged 35.13% in 2024.
• A 5-year view of Equity Average shows it stood at $219.9 million in 2022, then tumbled by 30.79% to $152.2 million in 2023, then sank by 32.48% to $102.7 million in 2024, then climbed by 0.33% to $103.1 million in 2025, then rose by 11.31% to $114.7 million in 2026.
• The last three Equity Average figures came in at $114.7 million (Q1 2026), $103.1 million (Q4 2025), and $91.3 million (Q3 2025), per Business Quant data.